Elacestrant, the leading oral drug candidate designed to degrade the estrogen receptor, continues to show prolonged antitumor activity, according to data presented at the ESMO Congress 2022. But not all oral selective estrogen receptor degraders have demonstrated impressive efficacy. In August, Sanofi announced that it was ending development of amcenestrant after an interim analysis of a pivotal phase III trial found that the study would likely end in failure.

中文翻译：

---

领先的口服 SERD 显示出长期的活性

根据 2022 年 ESMO 大会上公布的数据，Elacestrant 是旨在降解雌激素受体的领先口服候选药物，继续显示出持久的抗肿瘤活性。但并非所有口服选择性雌激素受体降解剂都表现出令人印象深刻的功效。8 月，赛诺菲宣布终止 Amcenestrant 的开发，此前对一项关键的 III 期试验进行的中期分析发现该研究很可能以失败告终。